On the Development of Plasma Protein Biomarkers
Open accessAbstract
The development of plasma biomarkers has proven to be more challenging than initially anticipated. Many studies have reported lists of candidate proteins rather than validated candidate markers with an assigned performance to a specific clinical objective. Biomarker research necessitates a clear rational framework with requirements on a multitude of levels. On the technological front, the platform needs to be effective to detect low abundant plasma proteins and be able to measure them in a high throughput manner over a large amount of samples reproducibly. At a conceptual level, the choice of the technological platform and available samples should be part of an overall clinical study design that depends on a joint effort between basic and clinical research. Solutions to these needs are likely to facilitate more feasible studies. Targeted proteomic workflows based on SRM mass spectrometry show the potential of fast verification of biomarker candidates in plasma and thereby closing the gap between discovery and validation in the biomarker development pipeline. Biological samples need to be carefully chosen based on well-established guidelines either for candidate discovery in the form of disease models with optimal fidelity to human disease or for candidate evaluation as well-designed and annotated clinical cohort groups. Most importantly, they should be representative of the target population and directly address the investigated clinical question. A conceptual structure of a biomarker study can be provided in the form of several sequential phases, each having clear objectives and predefined goals. Furthermore, guidelines for reporting the outcome of biomarker studies are critical to adequately assess the quality of the research, interpretation and generalization of the results. By being attentive to and applying these considerations, biomarker research should become more efficient and lead to directly translatable biomarker candidates into clinical evaluation.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Development of a clinically approved noninvasive biomarker assay from initial discovery is a long, difficult, and uncertain process.
“the development of such a test, from initial biomarker discovery to a clinically approved biomarker assay is a long, difficult, and uncertain process [22]”
From Update on biomarkers for the detection of endometriosis (2015) · cites this paper as [22]
Cited by
Sorted by citations
Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence
Chinen, A. B., Guan, C. M., Ferrer, J. R., Barnaby, S. N., Merkel, T. J., & Mirkin, C. A. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00321 · Cited by 1,030 · see citing works
Revisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917 · see citing works
“…statistical significance of the findings as well as specificity of potential biomarkers and their potential clinical application (Luque-Garcia & Neubert, 2007; Paulovich et al, 2008; Mischak et al, 2010; Surinova et al, 2011; Skates et al, 2013; Parker & Borchers, 2014; Hoofnagle et al, 2016).”
BackgroundPlasma Proteome Profiling to Assess Human Health and Disease
Geyer, P. E., Kulak, N. A., Pichler, G., Holdt, L. M., Teupser, D., & Mann, M. (2016) · Cell Systems · doi:10.1016/j.cels.2016.02.015 · Cited by 734 · see citing works
“The final clinical test for a biomarker identified by MS was to be performed with classical immunoassays (Anderson et al., 2009; Surinova et al., 2011).”
BackgroundPaxdb, a database of protein abundance averages across all three domains of life
Wang, M., Weiss, M., Simonovic, M., Haertinger, G., Schrimpf, S. P., Hengartner, M. O., & von Mering, C. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o111.014704 · Cited by 466 · see citing works
“…such measurements are arguably among the most biologically meaningful functional genomics data sets; they support multiple application scenarios, including genome annotation (5, 6), biomarker discovery (7, 8), posttranslational modification detection (9), and even environmental studies (10, 11).”
BackgroundMass spectrometry-based proteomics: existing capabilities and future directions
Angel, T. E., Aryal, U. K., Hengel, S. M., Baker, E. S., Kelly, R., Robinson, E. W., & Smith, R. D. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15331a · Cited by 443 · see citing works
The in silico human surfaceome
Bausch‐Fluck, D., Goldmann, U., Müller, S., van Oostrum, M., Müller, M., Schubert, O. T., & Wollscheid, B. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808790115 · Cited by 369 · see citing works
“Even though quantitative proteomic data can provide information about the actual abundance of a protein of interest in a specific subcellular location, the high dynamic range of protein abundances typically hinders the identification of low-abundance proteins (46).”
BackgroundSelf-citationVidová, V., & Spáčil, Z. (2017) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.01.059 · Cited by 353 · see citing works
“2 Left Panel represents stage II of a biomarker test development [106] (Fig.”
BackgroundPlasma Proteome Profiling to detect and avoid sample‐related biases in biomarker studies
Geyer, P. E., Voytik, E., Treit, P. V., Doll, S., Kleinhempel, A., Niu, L., Müller, J. B., Buchholtz, M., Bader, J. M., Teupser, D., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910427 · Cited by 348 · see citing works
“These discuss quality standards and emphasize the importance of selecting cohorts that are appropriate in size, thus ensuring the statistical significance of potential findings (2, 13-16).”
BackgroundMass-spectrometry-based proteomics: from single cells to clinical applications
Guo, T., Steen, J. A. J., & Mann, M. (2025) · Nature · doi:10.1038/s41586-025-08584-0 · Cited by 351 · see citing works
“Blood plasma, being in contact with all organs, has long been considered a treasure trove of potential biomarkers for various diseases 123,124 .”
Personalized protein corona on nanoparticles and its clinical implications
Corbo, C., Molinaro, R., Tabatabaei, M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Biomaterials Science · doi:10.1039/c6bm00921b · Cited by 314 · see citing works
Nakayasu, E. S., Gritsenko, M., Piehowski, P., Gao, Y., Orton, D., Schepmoes, A., Fillmore, T., Frohnert, B. I., Rewers, M., Krischer, J. P., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00566-6 · Cited by 281 · see citing works
“Veri fi cation and validation phases for selected biomarker candidates from discovery phase are mostly performed with targeted MS-based assays or targeted proteomics analysis 26,125,126 .”
BackgroundReproducible Quantification of Cancer-Associated Proteins in Body Fluids Using Targeted Proteomics
Hüttenhain, R., Soste, M., Selevsek, N., Röst, H. L., Sethi, A., Carapito, C., Farrah, T., Deutsch, E. W., Kusebauch, U., Moritz, R. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003989 · Cited by 245 · see citing works
Self-citationProteomics reveals the effects of sustained weight loss on the human plasma proteome
Geyer, P. E., Albrechtsen, N. J. W., Tyanova, S., Graßl, N., Iepsen, E. W., Lundgren, J. R., Madsbad, S., Holst, J. J., Torekov, S. S., & Mann, M. (2016) · Molecular Systems Biology · doi:10.15252/msb.20167357 · Cited by 235 · see citing works
“These profiles provide quantitative information on the majority of the classical, functional plasma proteins (Surinova et al, 2011), and we speculated that the metabolic status of individuals during weight loss and maintenance would be reflected by their plasma proteomes.”
Parker, C. E., & Borchers, C. H. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.006 · Cited by 238 · see citing works
“During the 15 or so years since its inception, mass spectrometry (MS) -based proteomics has led to the discovery and et al. (Surinova et al., 2011), and used with permission.”
BackgroundMethodInfluentialMass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease.
Kwong, G. A., von Maltzahn, G., Murugappan, G., et al. (2013) · PubMed · doi:10.1038/nbt.2464 · Cited by 213 · see citing works
Secreted proteins as a fundamental source for biomarker discovery
Št́astná, M., & Eyk, J. E. V. (2012) · PROTEOMICS · doi:10.1002/pmic.201100346 · Cited by 211 · see citing works
“Many of the potential protein biomarkers identified from these sources might be found circulating in the blood, which is a preferable way of patient clinical screening [9].”
BackgroundSajic, T., Liu, Y., & Aebersold, R. H. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400117 · Cited by 209 · see citing works
Self-citationMRM ‐based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma
Domański, D., Percy, A. J., Yang, J., Chambers, A. G., Hill, J. S., Freue, G. V. C., & Borchers, C. H. (2012) · PROTEOMICS · doi:10.1002/pmic.201100568 · Cited by 205 · see citing works
“Although there are more than 150 putative CVD biomarker proteins in the literature [3–5], validation of these biomarkers requires the analysis of thousands of samples [6].”
BackgroundZhang, J., Guy, M. J., Norman, H. S., Chen, Y.-C., Xu, Q., Dong, X., Guner, H., Wang, S., Kohmoto, T., Young, K. H., et al. (2011) · Journal of Proteome Research · doi:10.1021/pr200258m · Cited by 194 · see citing works
Update on biomarkers for the detection of endometriosis
Fassbender, A., Burney, R. O., F. O, D., D’Hooghe, T., & Giudice, L. (2015) · BioMed Research International · doi:10.1155/2015/130854 · Cited by 195 · see citing works
“Although there is consensus in the World Endometriosis Society that the development of a reliable noninvasive test is one of the top research priorities in endometriosis [11, 21], the development of such a test, from initial biomarker discovery to a clinically approved biomarker assay is a long, difficult, and uncerta…”
Relative and Absolute Quantitation in Mass Spectrometry–Based Proteomics
Ankney, J. A., Muneer, A., & Chen, X. (2018) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-061516-045357 · Cited by 182 · see citing works
Transformative Impact of Proteomics on Cardiovascular Health and Disease
Lindsey, M. L., Mayr, M., Gomes, A. V., Delles, C., Arrell, D. K., Murphy, A. M., Lange, R. A., Costello, C. E., Jin, Y.-F., Laskowitz, D. T., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000226 · Cited by 174 · see citing works
Panchaud, A., Affolter, M., & Kussmann, M. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2011.12.022 · Cited by 159 · see citing works
“platforms that deliver a large body of mechanistic insights and candidate biomarkers in life sciences [14,38,39].”
BackgroundCurrent Status and Advances in Quantitative Proteomic Mass Spectrometry
Wasinger, V. C., Zeng, M., & Yau, Y. Y. (2013) · International Journal of Proteomics · doi:10.1155/2013/180605 · Cited by 156 · see citing works
“This requires a lengthy and difficult process which involves candidate discovery, verification, validation, and translation to clinical laboratory use [12, 13].”
BackgroundFassbender, A., Vodolazkaia, A., Saunders, P., Lebovic, D., Waelkens, E., De Moor, B., & D'Hooghe, T. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.01.097 · Cited by 150 · see citing works
Røgeberg, M., Malerød, H., Røberg‐Larsen, H., Aass, C., & Wilson, S. R. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.05.006 · Cited by 149 · see citing works
Su, Y., Wu, D., Chen, J., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b02233 · Cited by 149 · see citing works
Déglon, J., Thomas, A., Mangin, P. J., et al. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-5161-6 · Cited by 140 · see citing works
“Regarding implementation of DBS in LC–MS–MS workflow (as discussed previously), direct DBS analysis may be a novel means of supporting the different stages in the biomarker pipeline from discovery to the validation steps [72].”
MethodRecent Advances in the Analysis of Complex Glycoproteins
Gaunitz, S., Nagy, G., Pohl, N. L. B., & Novotný, M. V. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04343 · Cited by 130 · see citing works
Mass spectrometric protein maps for biomarker discovery and clinical research
Liu, Y., Hüttenhain, R., Collins, B. C., & Aebersold, R. H. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2013.845089 · Cited by 123 · see citing works
Self-citationPan, S., Chen, R., Crispin, D. A., May, D., Stevens, T., McIntosh, M. W., Bronner, M. P., Ziogas, A., Anton‐Culver, H., & Brentnall, T. A. (2011) · Journal of Proteome Research · doi:10.1021/pr101148r · Cited by 118 · see citing works
Schutzer, S. E., Angel, T. E., Liu, T., Schepmoes, A., Clauss, T. R., Adkins, J., Camp, D., Holland, B. K., Bergquist, J., Coyle, P. K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017287 · Cited by 117 · see citing works
“Together these analyses represent the discovery phase of our studies on CFS and nPTLS, generating targets for follow up verification and validation in the later stages of the biomarker discovery workflow [13].”
MethodProbing the O-Glycoproteome of Gastric Cancer Cell Lines for Biomarker Discovery*
Campos, D., Freitas, D. P., Gomes, J., Magalhães, A., Steentoft, C., Gomes, C., Vester-Christensen, M. B., Ferreira, J. A., Afonso, L. P., Santos, L. L., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.046862 · Cited by 111 · see citing works
“Most broad proteomic studies for discovery of cancer biomarkers in serum have been designed to interrogate the proteome and not taking into account that cancer cells often produce aberrant glycoforms (1).”
BackgroundCancer biomarkers and their biosensors: A comprehensive review
Khan, H., Shah, M. R., Barek, J., & Malik, M. I. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116813 · Cited by 107 · see citing works
Tai, J., Fan, S., Ding, S., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.877193 · Cited by 103 · see citing works
Advances in high‐resolution accurate mass spectrometry application to targeted proteomics
Lesur, A., & Domon, B. (2014) · PROTEOMICS · doi:10.1002/pmic.201400450 · Cited by 101 · see citing works
“The relevance of such biomarker candidates needs to be verified in a representative set of patient samples, and ultimately validated in larger cohorts [2].”
BackgroundYoneyama, T., Ohtsuki, S., Honda, K., Kobayashi, M., Iwasaki, M., Uchida, Y., Okusaka, T., Nakamori, S., Shimahara, M., Ueno, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161009 · Cited by 100 · see citing works
“The selection of sample size to give sufficient statistical power for biomarker validation was based on previous reports [14,29].”
Pan, S., Chen, R., Brand, R. E., Hawley, S. J., Tamura, Y., Gafken, P. R., Milless, B. P., Goodlett, D. R., Rush, A. J., & Brentnall, T. A. (2012) · Journal of Proteome Research · doi:10.1021/pr201117w · Cited by 96 · see citing works
Fibronectin is a serum biomarker for D uchenne muscular dystrophy
Martin, F. C., Hiller, M., Spitali, P., Oonk, S., Dalebout, H., Palmblad, M., Chaouch, A., Guglieri, M., Straub, V. W., Lochmüller, H., et al. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201300072 · Cited by 94 · see citing works
“Abbreviations: BM, Bethlem myopathy; BMD, Becker muscular dystrophy; CK, creatine kinase; DMD, Duchenne muscular dystrophy; ETD, electron transfer dissociation; MG, myasthenia gravis; MMP, matrix metalloproteinase; TPP, Trans Proteomic Pipeline sis, classification and staging of diseases, patient stratification for in…”
BackgroundSimon, R., Girod, M., Fonbonne, C., Salvador, A., Clément, Y., Lantéri, P., Amouyel, P., Lambert, J. C., & Lemoine, J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018861 · Cited by 92 · see citing works
Simaeys, D. V., Turek, D., Champanhac, C., Vaizer, J., Sefah, K., Zhen, J., Sutphen, R., & Tan, W. (2014) · Analytical Chemistry · doi:10.1021/ac500466x · Cited by 87 · see citing works
Mass spectrometry for translational proteomics: progress and clinical implications
Baker, E. S., Liu, T., Petyuk, V., Burnum-Johnson, K., Ibrahim, Y., Anderson, G., & Smith, R. D. (2012) · Genome Medicine · doi:10.1186/gm364 · Cited by 88 · see citing works
Haider, A., Iqbal, S. Z., Bhatti, I. A., Alim, M., Waseem, M., Iqbal, M., & Khaneghah, A. M. (2024) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.13360 · Cited by 89 · see citing works
Hernández, B., Parnell, A. C., & Pennington, S. R. (2014) · PROTEOMICS · doi:10.1002/pmic.201300377 · Cited by 81 · see citing works
“LC-MS data have been used in many biomarker discovery experiments (for examples see [9, 10]).”
MethodHüttenhain, R., Choi, M., de la Fuente, L. M., Oehl, K., Chang, C.-Y., Zimmermann, A., Malander, S., Olsson, H. L., Šurinová, S., Clough, T., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001221 · Cited by 80 · see citing works
“Its dynamic protein concentration range spans 12 orders of magnitude, with few highly abundant proteins making up 90% of the plasma proteome (3, 4).”
BackgroundMethodInfluentialSelf-citationMüller, A. C., Breitwieser, F. P., Fischer, H., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr3002035 · Cited by 79 · see citing works
Proteomics, metabolomics and metagenomics for type 2 diabetes and its complications
Wang, N., Zhu, F., Chen, L., & Chen, K. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.09.035 · Cited by 81 · see citing works
MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum
Chambers, A. G., Percy, A. J., Simon, R., & Borchers, C. H. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.877346 · Cited by 77 · see citing works
“One justification for smallscale preliminary studies is that cancer biomarker proteins are often discovered in cell cultures or tissue samples and therefore their presence must be confirmed in plasma or serum [14,16].”
BackgroundCurrent trends in quantitative proteomics – an update
Li, H., Han, J., Pan, J., Liu, T., Parker, C. E., & Borchers, C. H. (2017) · Journal of Mass Spectrometry · doi:10.1002/jms.3932 · Cited by 74 · see citing works
Proteomics as a promising biomarker in food authentication, quality and safety: A review
Afzaal, M., Saeed, F., Hussain, M., et al. (2022) · Food Science & Nutrition · doi:10.1002/fsn3.2842 · Cited by 76 · see citing works
Tumor interstitial fluid — A treasure trove of cancer biomarkers
Gromov, P., Gromova, I., Olsen, C. J., Wielenga, V. T., Talman, M.-L., Serizawa, R., & Moreira, J. M. A. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.01.013 · Cited by 77 · see citing works
Discovery of serum protein biomarkers in drug-free patients with major depressive disorder
Lee, M. Y., Kim, E. Y., Kim, S. H., Cho, K.-C., Ha, K., Kim, K. P., & Ahn, Y. M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.04.009 · Cited by 74 · see citing works
“…experiment were further validated by MRM. MRM, also known as selected reaction monitoring (SRM), is a highly sensitive and reproducible verification platform that enables the quantification of a large number of candidate proteins in a single run in a high-throughput manner (Surinova et al., 2011).”
InfluentialBiomarkers in pharmacology and drug discovery
Anderson, D. C., & Kodukula, K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.026 · Cited by 70 · see citing works
Albrechtsen, N. J. W., Hornburg, D., Albrechtsen, R., Svendsen, B., Toräng, S., Jepsen, S. L., Kuhre, R. E., Hansen, M., Janus, C., Floyd, A. K., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.034 · Cited by 70 · see citing works
“Importantly, and in contrast to current targeted mass spectrometry-based detection methods (Fonslow et al., 2011; Gillette and Carr, 2013b; Keshishian et al., 2007b; Parker and Borchers, 2014; Surinova et al., 2011) (e.”
MethodResultThe application of quantification techniques in proteomics for biomedical research
Rodríguez‐Suárez, E., & Whetton, A. D. (2012) · Mass Spectrometry Reviews · doi:10.1002/mas.21347 · Cited by 69 · see citing works
“Nowadays, the most sensitive mass spectrometry method is SRM on a triple quadrupole (QQQ) platform which allows quantification of protein in plasma with a dynamic range of 4–5 orders of magnitude and a sensitivity of 1 mg/mL (Surinova et al., 2010).”
MethodTo label or not to label: Applications of quantitative proteomics in neuroscience research
Filiou, M. D., Martins‐de‐Souza, D., Guest, P. C., Bahn, S., & Turck, C. W. (2012) · PROTEOMICS · doi:10.1002/pmic.201100350 · Cited by 68 · see citing works
“Meaningful analysis of serum and plasma requires depletion of high-abundance proteins, often resulting in codepletion of low-abundance proteins of interest [73], which can only be avoided to a certain extent [74, 75].”
BackgroundProteomics and its applications for food authentication and food-technology research
Gallardo, J. M., Ortea, I., & Carrera, M. (2013) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2013.05.019 · Cited by 67 · see citing works
Hull, L. C., Farrell, D. F., & Grodzinski, P. A. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.08.003 · Cited by 64 · see citing works
“Many different categories of biomarkers have been identified such asmetabolites, peptides, proteins, cell-free nucleic acids, exosomes and circulating tumor cells (Findeisen and Neumaier, 2012; Hanash et al., 2008; Moon et al., 2011; Nagrath et al., 2007; Sawyers, 2008; Schwarzenbach et al., 2011; Sreekumar et al., 20…”
BackgroundMethodŠurinová, S., Hüttenhain, R., Chang, C.-Y., Pernas, L. E., Olga Vitek, A., & Aebersold, R. H. (2013) · Nature Protocols · doi:10.1038/nprot.2013.091 · Cited by 63 · see citing works
“An example is the validation of biomarkers, in which up to hundreds of candidate proteins are screened over clinical cohorts comprising hundreds of subjects 10 . and draw quantitative conclusions across different conditions or patient groups at the peptide or protein level ( Fig.”
BackgroundSelf-citationExtending the Depth of Human Plasma Proteome Coverage Using Simple Fractionation Techniques
Kaur, G., Poljak, A., Ali, S. A., Zhong, L., Raftery, M. J., & Sachdev, P. S. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00670 · Cited by 59 · see citing works
Emerging blood-based biomarkers for detection of gastric cancer
Kalniņa, Z. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i41.11636 · Cited by 62 · see citing works
Humphries, J. M., Penno, M. A. S., Weiland, F., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.01.018 · Cited by 60 · see citing works
“This is possibly because serum biomarkers that are able to distinguish early-stage GC are difficult to identify and validate due to the lack of serum samples from corresponding patients, the inherent difficulties of human genetic diversity and the relatively low abundance of potential serum biomarkers in comparison wi…”
BackgroundCilento, E. M., Jin, L., Stewart, T., Shi, M., Sheng, L., & Zhang, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14635 · Cited by 60 · see citing works
Clinical application of urinary proteomics/peptidomics
Albalat, A., Mischak, H., & Mullen, W. (2011) · Expert Review of Proteomics · doi:10.1586/epr.11.46 · Cited by 59 · see citing works
Biobank resources for future patient care: developments, principles and concepts
Végvári, Á., Welinder, C., Lindberg, H., Fehniger, T. E., & Marko‐Varga, G. (2011) · Journal of Clinical Bioinformatics · doi:10.1186/2043-9113-1-24 · Cited by 58 · see citing works
“In the last years, MRM multiplex assay have become very popular due to their generic concept [44,45].”
BackgroundFaria, S. S., Morris, C. F. M., Silva, A. R., da Fonseca, M. P., Forget, P., Castro, M. S., & Fontes, W. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00013 · Cited by 60 · see citing works
“In reality, different kinds of molecular targets have been used to discover biomarkers in blood/plasma/serum, body fluids, tissues, and their secretions (162).”
BackgroundChen, H., Chen, Y., Tsai, R., et al. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.11.019 · Cited by 56 · see citing works
Malignant Transformation and Associated Biomarkers of Ovarian Endometriosis: A Narrative Review
Михалева, Л. М., Davydov, A. I., Игоревна, П. О., Вячеславовна, М. Е., Nikolenko, V. N., Евгеньевна, Н. М., Klochkov, S. G., Somasundaram, S. G., Kirkland, C. E., & Aliev, G. M. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01363-5 · Cited by 59 · see citing works
Non‐invasive prognostic protein biomarker signatures associated with colorectal cancer
Šurinová, S., Radová, L., Choi, M., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404874 · Cited by 55 · see citing works
“Reliable and easily measurable biomarkers are intensely sought after to enable a more personalized patient management (Ludwig & Weinstein, 2005; Surinova et al, 2011).”
BackgroundSelf-citationRecent trends in analytical and structural glycobiology
Novotný, M. V., & Alley, W. R. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.05.029 · Cited by 55 · see citing works
“In-depth investigations of mammalian glycomes and glycoproteomes in complex biological samples are complicated by the very extensive concentration range in which various (glyco)proteins occur [18].”
BackgroundCancer biomarker determination by resonance energy transfer using functional fluorescent nanoprobes
Das, P., Sedighi, A., & Krull, U. J. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.07.060 · Cited by 55 · see citing works
Nissen, A., Bendixen, E., Ingvartsen, K. L., et al. (2012) · PROTEOMICS · doi:10.1002/pmic.201200231 · Cited by 54 · see citing works
“Fractionation of a sample can, however, often come at the price of adding technical variation to the analyses, which reduces reproducibility, and therefore data quality [54].”
BackgroundMass spectrometry-based proteomic quest for diabetes biomarkers
Shao, S., Guo, T., & Aebersold, R. H. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.12.012 · Cited by 54 · see citing works
Self-citationSystems Approach to Neurodegenerative Disease Biomarker Discovery
Lausted, C. G., Lee, I., Zhou, Y. F., Qin, S., Sung, J., Price, N. D., Hood, L., & Wang, K. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135928 · Cited by 52 · see citing works
“With the development of quantitative, high-performance MS in the past decade, its direct use as a discovery tool is now possible (72).”
BackgroundLan, J., Galindo, A. N., Doecke, J. D., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00788 · Cited by 52 · see citing works
Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression
Yang, H., Lyutvinskiy, Y., Herukka, S.-K., Soininen, H., Rutishauser, D., & Zubarev, R. A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132102 · Cited by 52 · see citing works
“This makes it a very challenging system to analyze with LC-MS that has a dynamic range of three to four orders of magnitude in direct (“discovery”) analysis and up to six orders in targeted analysis [12].”
BackgroundOrtea, I., Roschitzki, B., Ovalles-Bonilla, J. G., et al. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.09.011 · Cited by 52 · see citing works
Targeted Proteomics for Multiplexed Verification of Markers of Colorectal Tumorigenesis
Uzozie, A. C., Selevsek, N., Wåhlander, Å., Nanni, P., Grossmann, J., Weber, A., Buffoli, F., & Marra, G. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.062273 · Cited by 52 · see citing works
“The fact that our SRM assays failed to quantify 12 of the 40 proteins we targeted might be related to the detection limit we set for low-abundance proteins in our unfractionated, complex samples (54, 55), because it was higher than that used for fractionated peptide digests in our previous study (34).”
ResultBoudon, S., Ounaissi, D., Viala, D., Monteils, V., Picard, B. B., & Cassar‐Malek, I. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103685 · Cited by 52 · see citing works
Hüttenhain, R., Šurinová, S., Ossola, R., Sun, Z., Campbell, D. S., Cerciello, F., Schiess, R., Bausch‐Fluck, D., Rosenberger, G., Chen, J., et al. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.026617 · Cited by 50 · see citing works
“This region of the serum proteome is especially interesting because it is the protein abundance range where clinically relevant tissue leakage products reside (10).”
BackgroundSelf-citationKim, E. Y., Lee, J. W., Lee, M. Y., Kim, S. H., Mok, H. J., Ha, K., Ahn, Y. M., & Kim, K. P. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.04.029 · Cited by 50 · see citing works
Multinozzle Emitter Array Chips for Small-Volume Proteomics
Mao, P., Gómez-Sjöberg, R., & Wang, D. (2012) · Analytical Chemistry · doi:10.1021/ac3032965 · Cited by 50 · see citing works
Label-free mass spectrometry-based proteomics for biomarker discovery and validation
Pham, T. V., Piersma, S. R., Oudgenoeg, G., & Jiménez, C. R. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.31 · Cited by 50 · see citing works
Biomedical applications of nanoflares: Targeted intracellular fluorescence probes
Chenab, K. K., Eivazzadeh‐Keihan, R., Maleki, A. R., Pashazadeh‐Panahi, P., Hamblin, M. R., & Mokhtarzadeh, A. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.02.006 · Cited by 49 · see citing works
Precision cancer classification using liquid biopsy and advanced machine learning techniques
Eledkawy, A., Hamza, T., & El‐Metwally, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-56419-1 · Cited by 48 · see citing works
Targeted proteomics: a bridge between discovery and validation
Harlan, R., & Zhang, H. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.976558 · Cited by 46 · see citing works
Gao, R., Cui, X., Hao, Y., et al. (2015) · Talanta · doi:10.1016/j.talanta.2015.12.017 · Cited by 46 · see citing works
Titz, B., Gadaleta, R. M., Sasso, G. L., Elamin, A., Ekroos, K., Ivanov, N. V., Peitsch, M. C., & Hoeng, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092775 · Cited by 47 · see citing works
Cao, T. H., Jones, D. J. L., Voors, A. A., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1608 · Cited by 46 · see citing works
Simon, R., Enjalbert, Q., Biarc, J., et al. (2012) · Journal of Chromatography A · doi:10.1016/j.chroma.2012.09.059 · Cited by 45 · see citing works
Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?
Bresalier, R. S., Kopetz, S., & Brenner, D. E. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3575-2 · Cited by 44 · see citing works
“Why is this? Biomarker research is a phased process that includes a discovery phase (identifying promising markers), progressive validation phases (evaluation of the performance of markers in the intended clinical setting), and a clinical impact phase (does the marker improve patient outcomes?) [61, 62].”
BackgroundBilling, A. M., Hamidane, H. B., Bhagwat, A. M., Cotton, R. J., Dib, S. S., Kumar, P., Hayat, S., Goswami, N., Suhre, K., Rafii, A., et al. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.08.023 · Cited by 44 · see citing works
Geyer, P. E., Mann, S. P., Treit, P. V., & Mann, M. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002359 · Cited by 43 · see citing works
Proteomic Screening of Glycoproteins in Human Plasma for Frailty Biomarkers
Shamsi, K. S., Pierce, A. P., Ashton, A. S., Halade, D. G., Richardson, A. G., & Espinoza, S. E. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/glr224 · Cited by 44 · see citing works
Percy, A. J., Chambers, A. G., Parker, C. E., et al. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-405-0_13 · Cited by 43 · see citing works
Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease
Alberio, T., Pippione, A. C., Zibetti, M., Olgiati, S., Cecconi, D., Comi, C., Lopiano, L., & Fasano, M. (2012) · Scientific Reports · doi:10.1038/srep00953 · Cited by 43 · see citing works
Eid, C., Palko, J. W., Katilius, E., & Santiago, J. G. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00886 · Cited by 44 · see citing works
Teneurin protein family: An emerging role in human tumorigenesis and drug resistance
Ziegler, A., Corvalán, A. H., Roa, I. S., Brañes, J. A., & Wollscheid, B. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.07.021 · Cited by 43 · see citing works
Self-citationProtein biomarkers of alcohol abuse
Torrente, M. P., Freeman, W. M., & Vrana, K. E. (2012) · Expert Review of Proteomics · doi:10.1586/epr.12.38 · Cited by 42 · see citing works
Quantitative Proteomics Based on Optimized Data-Independent Acquisition in Plasma Analysis
Nouri-Nigjeh, E., Chen, R., Brand, R. E., Petersen, G. M., Chari, S. T., von Haller, P. D., Eng, J. K., Feng, Z., Yan, Q., Brentnall, T. A., et al. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00727 · Cited by 40 · see citing works
- Authors
- Surinova, S., Schiess, R., Hüttenhain, R., Cerciello, F., Wollscheid, B., & Aebersold, R.
- Affiliations
- University of Zurich (CH)
- Corresponding author
- Aebersold, Ruedi
- Venue
- Journal of Proteome Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-01-07
- Volume
- 10
- Issue
- 1
- Pages
- 5-16
- ISSN
- 1535-3893 (ISSN-L)
- 1535-3907
- OpenAlex
- W1965920802
- Cited by
- 334
- References
- 0
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 9 · 2023: 12 · 2022: 9 · 2021: 9 · 2020: 12 · 2019: 21 · 2018: 25 · 2017: 25 · 2016: 20 · 2015: 32 · 2014: 27 · 2013: 42 · 2012: 45
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Journal of Proteome Research (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Keywords
- plasma biomarkers, biomarker development, targeted proteomics, multiple reaction monitoring, biomarker validation, clinical research design, sample selection, disease models
- MeSH terms
- Animals, Blood Proteins, Humans, Mass Spectrometry, Biomarkers, Diagnostic Techniques and Procedures, Proteomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
